Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug clinical trial reporting still dangerously inadequate, says BMJ

This article was originally published in SRA

Executive Summary

The British Medical Journal has published seven research papers that provide a damning indictment of current practice in pharmaceutical clinical trial reporting1. According to an accompanying editorial by senior research fellow Richard Lehman and clinical epidemiology editor Elizabeth Loder, the articles confirm that "a large proportion of evidence from human trials is unreported, and much of what is reported is done so inadequately"2. They contend that this leads to unnecessary harm to patients and costs to health systems.

You may also be interested in...



Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19

Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.

Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society

French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.

Sanofi’s New Loan Offers Win-Win Model For Pharma And Society

Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel